Literature DB >> 22160382

Mechanisms and clinical significance of BIM phosphorylation in chronic lymphocytic leukemia.

Alex Paterson1, C Ian Mockridge, Jemimah E Adams, Sergey Krysov, Kathleen N Potter, Andrew S Duncombe, Simon J Cook, Freda K Stevenson, Graham Packham.   

Abstract

B-cell receptor and microenvironment-derived signals promote accumulation of chronic lymphocytic leukemia (CLL) cells through increased proliferation and/or decreased apoptosis. In this study, we investigated the regulation of BIM, a proapoptotic BCL2-related protein, which is tightly regulated by phosphorylation. Surface IgM stimulation increased phosphorylation of 2 BIM isoforms, BIM(EL) and BIM(L), in a subset of CLL samples. In contrast, in normal B cells, anti-IgM triggered selective phosphorylation of BIM(EL) only. In CLL, anti-IgM-induced BIM phosphorylation correlated with unmutated IGHV gene status and with progressive disease. Strikingly, it was also associated with progressive disease within the mutated IGHV gene subset. BIM phosphorylation was dependent on MEK1/2 kinase activity, and we identified BIM(EL) serine 69, previously linked to pro-survival responses, as the major site of phosphorylation in CLL and in Ramos cells. BIM(EL)/BIM(L) phosphorylation was associated with release of the pro-survival protein MCL1. Coculture of CLL cells with HK cells, a model of the CLL microenvironment, promoted CLL cell survival and was associated with MEK1/2 activation and BIM(EL) phosphorylation. Hence, BIM phosphorylation appears to play a key role in apoptosis regulation in CLL cells, potentially coordinating antigen and microenvironment-derived survival signals. Antigen-mediated effects on BIM may be an important determinant of clinical behavior.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22160382     DOI: 10.1182/blood-2011-07-367417

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  30 in total

1.  The phosphatidylinositol-3-kinase inhibitor NVP-BKM120 overcomes resistance signals derived from microenvironment by regulating the Akt/FoxO3a/Bim axis in chronic lymphocytic leukemia cells.

Authors:  Laia Rosich; Ifigènia Saborit-Villarroya; Mónica López-Guerra; Sílvia Xargay-Torrent; Arnau Montraveta; Marta Aymerich; Neus Villamor; Elias Campo; Patricia Pérez-Galán; Gaël Roué; Dolors Colomer
Journal:  Haematologica       Date:  2013-07-12       Impact factor: 9.941

Review 2.  Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia.

Authors:  Adrian Wiestner
Journal:  Blood       Date:  2012-08-08       Impact factor: 22.113

Review 3.  Novel and emerging targeted-based cancer therapy agents and methods.

Authors:  Mohammad Hojjat-Farsangi
Journal:  Tumour Biol       Date:  2015-02-09

4.  Duvelisib treatment is associated with altered expression of apoptotic regulators that helps in sensitization of chronic lymphocytic leukemia cells to venetoclax (ABT-199).

Authors:  V M Patel; K Balakrishnan; M Douglas; T Tibbitts; E Y Xu; J L Kutok; M Ayers; A Sarkar; R Guerrieri; W G Wierda; S O'Brien; N Jain; H M Stern; V Gandhi
Journal:  Leukemia       Date:  2016-12-26       Impact factor: 11.528

5.  Integration of B-cell receptor-induced ERK1/2 phosphorylation and mutations of SF3B1 gene refines prognosis in treatment-naïve chronic lymphocytic leukemia.

Authors:  Chiara Cavallini; Carlo Visco; Santosh Putta; Davide Rossi; Elda Mimiola; Norman Purvis; Ornella Lovato; Omar Perbellini; Erika Falisi; Monica Facco; Livio Trentin; Maria G Romanelli; Gianpietro Semenzato; Achille Ambrosetti; Gianluca Gaidano; Giovanni Pizzolo; Alessandra Cesano; Maria T Scupoli
Journal:  Haematologica       Date:  2016-12-07       Impact factor: 9.941

6.  The Nedd8-activating enzyme inhibitor MLN4924 thwarts microenvironment-driven NF-κB activation and induces apoptosis in chronic lymphocytic leukemia B cells.

Authors:  J Claire Godbersen; Leigh Ann Humphries; Olga V Danilova; Peter E Kebbekus; Jennifer R Brown; Alan Eastman; Alexey V Danilov
Journal:  Clin Cancer Res       Date:  2014-03-15       Impact factor: 12.531

7.  Chronic lymphocytic leukemia (CLL) risk is mediated by multiple enhancer variants within CLL risk loci.

Authors:  Huihuang Yan; Shulan Tian; Geffen Kleinstern; Zhiquan Wang; Jeong-Heon Lee; Nicholas J Boddicker; James R Cerhan; Neil E Kay; Esteban Braggio; Susan L Slager
Journal:  Hum Mol Genet       Date:  2020-09-29       Impact factor: 6.150

8.  Association between B-cell receptor responsiveness and disease progression in B-cell chronic lymphocytic leukemia: results from single cell network profiling studies.

Authors:  Alessandra Cesano; Omar Perbellini; Erik Evensen; Charles C Chu; Federica Cioffi; Jason Ptacek; Rajendra N Damle; Roberto Chignola; James Cordeiro; Xiao-jie Yan; Rachael E Hawtin; Ilaria Nichele; Jodi R Ware; Chiara Cavallini; Ornella Lovato; Roberta Zanotti; Kanti R Rai; Nicholas Chiorazzi; Giovanni Pizzolo; Maria T Scupoli
Journal:  Haematologica       Date:  2012-11-09       Impact factor: 9.941

Review 9.  Getting away with murder: how does the BCL-2 family of proteins kill with immunity?

Authors:  Thibaud T Renault; Jerry E Chipuk
Journal:  Ann N Y Acad Sci       Date:  2013-03-25       Impact factor: 5.691

10.  Bim, a proapoptotic protein, up-regulated via transcription factor E2F1-dependent mechanism, functions as a prosurvival molecule in cancer.

Authors:  Raghu Gogada; Neelu Yadav; Junwei Liu; Shaohua Tang; Dianmu Zhang; Andrea Schneider; Athul Seshadri; Leimin Sun; C Marcelo Aldaz; Dean G Tang; Dhyan Chandra
Journal:  J Biol Chem       Date:  2012-11-14       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.